Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

New research: MRI can help detect early stage Alzheimer's disease

New research suggests that magnetic resonance imaging could help detect Alzheimer's disease at an early stage, before irreversible damage has occurred, according to a new study published online and in the June print edition of Radiology.

12 Apr 2011

Alzheimer’s drug – a failure of sorts: Study

Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.

11 Apr 2011

Air pollution on freeways may lead to brain damage: Study

Earlier research has shown that air pollution from cars and trucks on Southern California freeways – that contains soot, pavement dust and other toxic substances - can cause respiratory disease, heart attacks, cancer and premature death. Now a new study has shown that exposure to pollution particles roughly one-thousandth the width of a human hair may lead to brain damage in mice, including signs associated with memory loss and Alzheimer’s disease. The study comes from University of Southern California and is published in the journal Environmental Health Perspectives.

10 Apr 2011

Canadian political parties called upon to focus on health system during election campaign

The Health Action Lobby today called on all political parties to focus on the health system during the federal election campaign. HEAL is a coalition of 35 national health organizations that represents a broad cross-section of health providers, health regions, institutions & facilities.

8 Apr 2011

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Targacept, Inc. today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research in Colorado Springs, Colorado.

8 Apr 2011

CoMeD urges UN to ban mercury use in pharmaceuticals

While the United Nations actively questions the use of a vaccine preservative that contains the known neurotoxin mercury, the Coalition for Mercury-Free Drugs, a Maryland-based, non-profit organization, is urging the UN to ban it.

7 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Novel strategy to build molecular probes may lead to development of new cancer drugs

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses.

7 Apr 2011

Study explores physical effect of freeway pollution on brain cells

If mice commuted, their brains might find it progressively harder to navigate the maze of Los Angeles freeways.

7 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

PharmaPraxis, from Axis Biotec, Cryopraxis, Silvestre Labs and CellPraxis Group, announces the formalization of an agreement with Brazil's Ministry of Health to manufacture biologic drugs.

7 Apr 2011

Chemical senses scientists to hold 33rd annual meeting, April 13-17, 2011

The Association for Chemoreception Sciences (AChemS), a US-based scientific organization, is holding its 33rd annual meeting. About 700 scientists are gathering to present new information on the role of smell and taste in disease, nutrition, and social interactions in humans as well as animals. Smell and taste play essential roles in our daily lives.

6 Apr 2011

SWHR roundtable to examine sex differences in Alzheimer's disease

At the Women's Health 2011: 19th Annual Conference plenary session, A Wake Up Call to Clinicians: Alzheimer's and Early Diagnosis, Geoffrey Beene Foundation President, Meryl Comer announced the Society for Women's Health Research's upcoming one-day Alzheimer's roundtable, exploring sex differences in this increasingly prevalent disease.

6 Apr 2011

High clusterin levels linked to Alzheimer's prevalence and severity

Higher levels in blood of the protein clusterin, also known as apolipoprotein J, are significantly associated with the prevalence and severity of Alzheimer's disease, but not with the risk of onset of new disease, according to a study in the April 6 issue of JAMA.

6 Apr 2011

MRIs can help predict MCI individuals at greatest risk for developing Alzheimer's disease

Using MRI, researchers may be able to predict which adults with mild cognitive impairment are more likely to progress to Alzheimer's disease, according to the results of a study published online and in the June issue of Radiology.

6 Apr 2011

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.

5 Apr 2011

Quest Diagnostics completes Athena Diagnostics acquisition

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific.

From Quest Diagnostics 4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011